title: Vasoactive Intestinal Peptide (VIP) Nanoparticles for Diagnostics and for Controlled and Targeted Drug Delivery.
abstract: Neuropeptides are potentially valuable tools for clinical applications as they offer many distinct advantages over other bioactive molecules like proteins and monoclonal antibodies due to their reduced side effects and simple chemical modifications. Despite such advantages, the difficulty with neuropeptides often relies on their poor metabolic stability and reduced biological activity intervals. Among the neuropeptides, VIP has been identified as a potentially bioactive agent for inflammatory, neurodegenerative, and cancer-related diseases. However, the effective translation of preclinical studies related to VIP to clinical realities faces several major challenges, most of which are commonplace for other neuropeptides. Here, we present recent studies aimed at developing nanostructured organic and inorganic systems either for the appropriate delivery of VIP or for VIP targeting. These technologies stand as an alternative starting point for chemical manipulations of the neuropeptides in order to improve potency, selectivity, or pharmacokinetic parameters.
authors.affiliation: CABIMER-Andalusian Center for Molecular Biology and Regenerative Medicine (CSIC-University of Seville-UPO), Seville, Spain; Department of Medical Biochemistry, Molecular Biology and Immunology, The University of Seville Medical School, Seville, Spain.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Klippstein
authors.affiliation: CABIMER-Andalusian Center for Molecular Biology and Regenerative Medicine (CSIC-University of Seville-UPO), Seville, Spain; Department of Medical Biochemistry, Molecular Biology and Immunology, The University of Seville Medical School, Seville, Spain. Electronic address: david.pozo@cabimer.es.
authors.forename: David
authors.initials: D
authors.lastname: Pozo
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology; D016503:Drug Delivery Systems / Q000379:methods*; D015870:Gene Expression; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D058990:Molecular Targeted Therapy; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D011485:Protein Binding; D018005:Receptors, Vasoactive Intestinal Peptide / Q000235:genetics / Q000378:metabolism; D055672:Static Electricity; D057170:Translational Research, Biomedical; D014660:Vasoactive Intestinal Peptide / Q000737:chemistry* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D018005:Receptors, Vasoactive Intestinal Peptide; D014660:Vasoactive Intestinal Peptide
keywords: Cancer; Drug delivery; Immunomodulation; Malignant tumor; Nanoparticles; Neuropeptides; VIP receptors; Vasoactive intestinal peptide